IDIgor' Leonidovich Davydkin

Igor' Leonidovich Davydkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Igor' Leonidovich Davydkin has a total of 313 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetic polymorphisms in the development of anthracycline-induced cardiovascular toxicity in patients with follicular lymphoma

    by G. R. Gimatdinova, O. E. Danilova, Y. N. Milyutkina, A. S. Sustretov, P. V. Ilyasov, I. L. Davydkin, Г. Р. Гиматдинова, О. Е. Данилова, Ю. С. Милюткина, А. С. Сустретов, et al.

    Aim . To identify genetic variants associated with the risk of developing anthracycline-induced cardiovascular toxicity during antitumor therapy in patients with follicular lymphoma. Material and methods. The prospective study included 83 patients diagnosed with non-Hodgkin B-cell follicular lymphoma who received chemotherapy. Based on the results of follow-up standard and speckle-tracking echocardiography, the patients were divided into 2 groups: Group 1 — median age 59.0 (51.5; 69.0) years old, of which 44.1% were men (n=15), Group 2 — median age 55.0 (47.0; 66.5) years old, of which 55.1% were men (n=27)). Clinical, demographic, and laboratory assessments were performed, including high-throughput sequencing. Results . Minor alleles of rs2072708, rs2072710, rs2075939 NCF4, rs1443638, rs2306422, rs72547284, rs11661275 CELF4, CYBA, and FHOD3; rs246232 ABCC1; rs3749442 ABCC5 are associated with an increased risk of anthracycline-induced cardiovascular toxicity. Minor alleles of rs2233260, rs3833910, rs7232329, rs8096379, rs200571909, rs625223, rs2566514 MYL2, MYOM1, NEB and NOS3; rs1128503, rs2032582, rs2214102, rs2235013, rs2235033, rs4728699 ABCB1; rs212088, rs35604 ABCC1; rs1056892 and rs2835286 CBR3; rs1549758 NOS3, rs3731750 TTN is associated with a reducedlikelihood of complications. Conclusion . This study identified several novel genetic variants associated with the risk of cardiovascular toxicity, highlighting the potential for developing personalised approaches to anticancer therapy.

  • Open Access

    Optimization of the diagnosis of cardiovascular adverse events in patients with non-Hodgkin lymphomas

    by G. R. Gimatdinova, O. E. Danilova, O. A. Rubanenko, A. V. Kontsevaya, I. L. Davydkin, D. D. Tsyrenov

    Aim.  To identify the optimal combination of cardiovascular toxicity (CVT) markers for subsequent optimization of the diagnosis of cardiovascular adverse events in patients with non-Hodgkin lymphomas. Material and methods.  This prospective study was conducted to monitor cardiovascular adverse events in patients treated with the R-CHOP regimen. A total of 116 patients were divided into main (n=58, mean age 55,4±12,4 years, 25 (43,1%) men) and control groups (n=58, mean age 54,9±11,4 years, 32 (55,1%) men). Division of patients into subgroups was carried out taking into account CVT: A1 and B1 — with CVT: A1 — 21 patients, 55,9±11,17 years, 15 men (71,4%); B1 — 10 patients, 56,75±9,11 years, 6 men (60%); A2 — 37 patients, 55,16±13,12 years, 13 men (35,1%); B2 — 48 patients, mean age 54,24±12,18 years, men n=28 (58,3%). Results.  CVT was more common in men (p=0,039, p A1-A2 =0,008, p A2-B2 =0,031) and smokers (p=0,026, p A1-A2 =0,04, p A2-B2 =0,046, p A2-B1 =0,004). The level of N-terminal pro-brain natriuretic peptide (NT-proBNP) significantly increased from 86,50 (68,50;113,50) to 150,50 (71,00;372,50) pg/ml (p=0,023, p V2-V3 =0,026) in the target group of patients. Among patients with CVT, a longer QTc was recorded, as well as a lower level of global longitudinal systolic strain (p=0,008, Visit 2, p=0,003, Visit 3). Conclusion.  The mathematical model developed by the authors, based on paraclinical parameters and allowing for CVT diagnosis optimization, is proposed for use in real-world practice.

  • Biomarkers for Monitoring R-CHOP-associated Cardiotoxicity in Patients with Non-hodgkin Lymphoma

    by G.R. Gimatdinova, O.E. Danilova, I.L. Davydkin

    Introduction: Antineoplastic therapy may exert toxic effects on multiple organ systems in patients with hematologic malignancies. This is particularly relevant for individuals with indolent non-Hodgkin lymphoma treated with anthracycline-containing regimens, which carry a well-documented risk of cardiotoxicity. Materials and Methods: A case–control study was conducted at medical institutions in Samara, Russia, enrolling 72 patients diagnosed with grade 1–2 follicular B-cell non-Hodgkin lymphoma. All participants were administered six cycles of R-CHOP immunochemotherapy as clinically indicated. The primary objective was to identify early biomarkers of treatment-related cardiotoxicity. Results: The study identified three parameters as the most sensitive indicators of cardiovascular toxicity: prolongation of the corrected QT interval (QTc), reduction in left ventricular global longitudinal strain, and elevation of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) levels. Additionally, the authors propose prognostic models to predict the presence of cardiotoxicity at 3 and 6 months of treatment. Discussion: Comparison of the study’s findings with previously published data revealed full consistency with the existing medical literature and further substantiates the authors' assertion regarding the prognostic utility of the identified laboratory and instrumental markers in the early detection of cardiotoxicity. Conclusion: Incorporating these biomarkers into routine cardiovascular monitoring protocols facilitates early detection of cardiotoxicity in patients with hematologic malignancies, enabling timely therapeutic adjustments and optimizing clinical management.

  • A clinical case of metabolic nephropathy with severe proteinuria

    by L. A. Rogozina, O. A. Vorobyeva, Iu. A. Gergel, T. E. Nichik, I. L. Davydkin

    Globally, the prevalence of chronic kidney disease (CKD) is approaching epidemic levels. Some CKD phenotypes of secondary etiology are characterized by slow progression with a prolonged period of asymptomatic progression, does not reach nephrotic levels. Assessing prognostic markers in the early stages of CKD is essential to reduce the risk of progression to kidney dysfunction and cardiovascular disease through timely pathogenetic correction. This should be addressed not only by nephrologists but also by other primary care practitioners. This article describes a 64-year-old male patient with obesity, episodes of hyperglycemia, and long-standing arterial hypertension. Biochemical analysis confirms hyperglycemia, hyperuricemia, and dyslipidemia. Morphological studies indicate the development of secondary segmental glomerulosclerosis, including in the vascular pole of the glomeruli. Autoimmune pathology has been excluded. Urinalysis revealed episodes of proteinuria up to 4.2 g per day. After adequate treatment of hypertension, dyslipidemia, hyperglycemia, and hyperuricemia, a decrease in proteinuria was observed. The evaluation and treatment of these patients requires a comprehensive approach, with the mandatory participation of nephrologists and endocrinologists.when proteinuria

  • Open Access

    Markers Determining the Risk of Cardiovascular Toxicity Against the Background of Antitumor Immunochemotherapy

    by R. F. Gimranova, G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, O. A. Rubanenko

    Introduction. Malignant neoplasms occupy a leading place among the causes of death in the population. Despite the fact that antitumor treatment can significantly prolong the life of cancer patients, it continues to have a toxic effect on organs and systems. Patients with non-Hodgkin’s lymphoma of the indolent type receiving anthracycline-containing therapy regimens, which are the leading treatment regimens due to their availability from the pharmacological and financial side in the Russian Federation, are no exception. The purpose of the study. To identify clinical, laboratory and instrumental indicators, assessed after 3 months of treatment, determining the risk of developing cardiovascular toxicity against the background of 6-month antitumor immunochemotherapy according to the R-CHOP scheme in patients with indolent type of non-Hodgkin’s lymphomas. Materials and methods. An observational case-control study was conducted on the bases of medical institutions in Samara for patients diagnosed with B-cell follicular lymphoma, who were shown to undergo 6 courses of immunochemotherapy in the R-CHOP mode. The patients were divided into two groups: the main group n=21 (16 (76.2 %) men, average age 55.2(9.8) years) with verified cardiovascular toxicity and the control group n=51 (21 (41.2 %) men, average age 53.7(13.6) years) without her. During treatment, the targets were evaluated in two stages: at the start and after three courses of therapy. Results. At the start of the study, patients with verified cardiovascular toxicity had higher values of BMI, CDR, CDR, CDR, volume of the left and right atria, and distal diameter of the excretory tract compared with the control group (p < 0.05). Also, in patients with cardiovascular toxicity, the QTc significantly prolonged during treatment from 360 (245.0; 411.0) to 412 (279.0; 450.0) msec., p=0.032; the concentration of NTproBNP increased from 77 (67.0; 109.0) to 110 (75.0; 222.0) mg/ml, p=0.032; and the value of GLS LV decreased from -21.1 (19.7; 22.4) to -17.7 (15.1; 21.0)%, p=0.004. Conclusion. The expansion of diagnostic protocols within the framework of cardiovascular toxicity among patients with B-cell follicular lymphoma allows timely optimization of management tactics for patients with oncohematological profile.

  • Наследственная тромбофилия и хроническая демиелинизирующая полинейропатия: клинический случай

    by Кирилл Константинович Носков, Александра Владимировна Беспалова, Тарас Алексеевич Гриценко, Ксения Викторовна Борисова, Игорь Леонидович Давыдкин

    Тромбофилия представляет собой состояние повышенной склонности крови к патологическому внутрисосудистому свертыванию, обусловленное наследственными и/или приобретенными факторами риска, что может вызывать как венозные, так и артериальные эмболии и тромбозы. Представляем клинический случай пациентки 45 лет с сочетанием мультифакторной тромбофилии (наследственной – мутация Лейден, гематогенной – гипергомоцистеинемия и повышенные уровни факторов свертывания) и хронической воспалительной демиелинизирующей полинейропатии (ХВДП). Клиническая картина включала рецидивирующие тромбозы глубоких вен нижних конечностей, прогрессирующее неврологическое ухудшение, включая чувствительные нарушения, сенситивную атаксию и нейропатический болевой синдром. Особую сложность представляла дифференциальная диагностика между проявлениями ХВДП и возможными ишемическими осложнениями, связанными с тромбофилией. Случай подчеркивает важность более глубокого понимания патогенетических взаимосвязей между тромбофилией и неврологическими заболеваниями, а также персонализированного подхода к диагностике и лечению пациентов с сочетанной патологией, включая тщательный анализ генетических, гематологических и неврологических данных. Thrombophilia is characterized by an increased predisposition of the blood to abnormal intravascular clotting, resulting from both hereditary and/or acquired risk factors, which can lead to venous or arterial thrombosis and embolism. Here we present a clinical case of a 45‑year-old patient with a combination of multifactorial thrombophilia (hereditary – Leiden mutation; hematogenous – hyperhomocysteinemia and elevated coagulation factors level) and chronic inflammatory demyelinating polyneuropathy (CIDP). The clinical presentation encompassed recurrent deep vein thrombosis in the lower extremities, progressive neurological decline marked by sensory deficits, sensory ataxia, and neuropathic pain syndrome. A particularly challenging aspect was the differential diagnosis between CIDP manifestations and potential ischemic complications linked to thrombophilia. The case underscores the necessity for a deeper comprehension of the pathogenetic interplay between thrombophilia and neurological disorders, as well as the importance of a personalized approach to diagnosing and treating patients with combined pathologies, incorporating a comprehensive analysis of genetic, hematological, and neurological data.

  • Open Access

    Feasibility of telemonitoring in hematology patients: a narrative review

    by P. V. Osadchaya, A. A. Garanin, I. L. Davydkin

    Literature data presented in open medical sources on the use of telemedicine in hematology were analyzed. Telemedicine is an effective way to manage and monitor patients in order to minimize in-person hospital visits when this can be avoided. The experience and perspectives of this type of interaction in terms of patient satisfaction and effectiveness in monitoring various hematologic diseases have been studied. Despite the small number of results with high evidence, the studies demonstrate an optimistic picture of the use of telemedicine in real clinical practice, which leads to the need for more large-scale and high-quality studies to introduce various forms of telemonitoring in the routine follow-up of hematologic patients.


  • Open Access

    Factors, Associated with Mortality in Patients with Chronic Heart Failure

    by Olesya Rubanenko, Anatoly Rubanenko, Inna Skripnik, Kristina Matyukhina, Igor Davydkin, Dmitry Duplyakov

    Chronic heart failure (CHF) is one of the leading causes of mortality. Many factors may influence the risk of mortality in patients with CHF. Therefore, predictors of mortality in patients with CHF should be clarified. Aim of the study was to determine predictors of unfavorable prognosis in patients with CHF. Methods. 591 patients (median age 71.0 (64.0-80.0) years, 339 (57.4%) men) with CHF were enrolled into the “Samara Region Registry of CHF” during 1-month period in 2022 at 60 centers. The follow-up period was 18 months. During follow-up period 198 (33.5%) patients died. Results. Prognostic factors associated with mortality in patients with CHF according to the results of multivariate analysis were age (OR 1.034, 95% confidence interval (CI) 1.018-1.051, p<0.001), LVEF < 40% (OR 1.381, 95% CI 1.014-1.880, p=0.040), NYHA IV class (OR 1.932, 95% CI 1.354-2.757), p<0.001), oxygen therapy at outpatients (OR 2.668, 95% CI 1.482-4.802, p=0.001), in-hospital inotropic therapy (OR 1.463, 95% CI 0.972-2.201, p=0.068), ascites (OR 1.543, 95% CI 0.982-2.425, p=0.06), gender (male) (OR 1.354, 95% CI 0.971-1.887, p=0.074). Previous cardiovascular surgery had an inverse relationship with the probability of death (OR 0.481, 95% CI 0.322-0.718, p<0.001). Conclusions. Predictors of mortality in patients with CHF during 18-months follow-up were age, LVEF<40%, NYHA IV class of CHF, oxygen therapy in outpatient, in-hospital inotropic therapy, ascites and male gender. Previous cardiovascular surgery had favourable effect on mortality in these patients.

  • Open Access

    Genetic predictors of cardiovascular toxicity in oncohematological patients

    by G. R. Gimatdinova, O. E. Danilova, I. L. Davydkin, Yu. S. Milyutkina, A. S. Sustretov, O. A. Germanova

    Aim. To identify single nucleotide polymorphisms reliably associated with cardiovascular toxicity in oncohematological patients receiving antitumor immunochemotherapy.Material and methods. For the study, 34 patients with an established diagnosis of non-Hodgkin's B-cell follicular lymphoma were prospectively selected at the Clinic of the Samara State Medical University, who were indicated for antitumor immunochemotherapy according to the R-CHOP protocol. During the follow-up, the patients were divided into 2 following groups: the main group consisted of 12 patients with cardiovascular toxicity (mean age, 42,4 (2,8) years, including men — n=3 (25%)), the control group — 22 patients without cardiovascular toxicity (mean age, 39,8 (1,7), including men — n=8 (36%)). Cardiovascular toxicity was verified on the basis of a combination of specific cardiological complaints with a decrease in the left ventricular ejection fraction >10% from the baseline or in absolute terms less than 53% and/or a decrease in the left ventricular longitudinal systolic strain >12% from the baseline and/or an increase in NT-proBNP >125 pg/ml.Results. The study presents the identified genetic features in oncohematological patients in the context of cardiovascular toxicity. ABCC5 rs1879257, PRKAG2 rs13224758, RYR2 rs10925391 and SLC22A7 rs414917 variants had a significant association with an increased risk of cardiovascular toxicity in the target group of patients by 5-6 times. In addition, the ABCB1 rs2032582 variant showed the opposite effect and was associated with a reduced risk of cardiovascular complications, having a protective effect on the cardiovascular system.Conclusion. Although further studies are needed to confirm the diagnostic and prognostic significance of the detected genetic variants, the study results indicate the prospects of genetic screening before antitumor immunochemotherapy as a future tool for stratifying oncohematological patients and minimizing cardiovascular toxicity.

  • Open Access

    Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)

    by Kathelijn Fischer, Riitta Lassila, Flora Peyvandi, Alexander Gatt, Samantha C. Gouw, Rob Hollingsworth, Thierry Lambert, Radek Kaczmarek, Diana Carbonero, Mike Makris, et al.